Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7441 to 7455 of 7707 results

  1. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

    Technology appraisal guidance
    Discontinued

  2. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued [GID-TAG382]

    Technology appraisal guidance
    Discontinued

  3. Atrial fibrillation - ximelagatran [ID376]

    Discontinued [GID-TAG377]

    Technology appraisal guidance
    Discontinued

  4. Diabetic retinopathy - ruboxistaurin [ID382]

    In development [GID-TAG386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development [GID-TAG406] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Scleroderma: oral mycophenolate (ESUOM32)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Evidence summary
    Published
    29 July 2014

  7. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued [GID-TA10066]

    Technology appraisal guidance
    Discontinued

  8. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued [GID-TA10047]

    Technology appraisal guidance
    Discontinued

  9. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued [GID-TA10045]

    Technology appraisal guidance
    Discontinued

  10. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued [GID-TA10072]

    Technology appraisal guidance
    Discontinued

  11. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    In development [GID-TA11357] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

    Technology appraisal guidance
    Discontinued

  13. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued [GID-TAG321]

    Technology appraisal guidance
    Discontinued

  14. Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

    Discontinued [GID-TAG300]

    Technology appraisal guidance
    Discontinued

  15. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued [GID-TAG278]

    Technology appraisal guidance
    Discontinued